Boehringer Introduces LENZELTA Vaccine for Mastitis Control
INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
INGELHEIM, GERMANY, April 13, 2026 Boehringer Ingelheim has introduced LENZELTA®, a new veterinary vaccine designed to prevent mastitis in...
Los Angeles, CA – October 22, 2025 — Armata Pharmaceuticals, Inc., a biotechnology company advancing bacteriophage-based therapeutics, announced positive...
